So its entirely reasonable to ask how drugs that enhance insulin action such as GLP-1 medications like semaglutide or tirzepatide can reduce harmful visceral fat, lower the risk of heart attack and stroke, and possibly even influence long-term cancer risk
Meta-analyses of berberine studies suggest more modest effects, with HbA1c reductions of approximately 0.50.7% and variable weight loss, typically 13 kg over several months
Accordingly, clinical studies are afforded the ability to collect whole blood into several different anticoagulant-coated tubes, which is not typically feasible in preclinical studies
Unfortunately, there are no drugs specifically approved for the treatment of NAFLD at present (93)
Even if the drug caused fewer cravings, the instinct to use food or restriction to manage emotions was still there
The worst-case scenario is not treating obesity at all and experiencing progressive metabolic deterioration, cardiovascular disease, diabetes, and reduced quality of life over decades